Evaxion A/S Files October 2025 6-K Report

Ticker: EVAX · Form: 6-K · Filed: 2025-10-14T00:00:00.000Z

Sentiment: neutral

Topics: reporting, foreign-private-issuer, regulatory-filing

Related Tickers: EVX

TL;DR

Evaxion A/S (EVX) filed its monthly 6-K report on Oct 14, 2025, confirming its status as a foreign private issuer.

AI Summary

Evaxion A/S filed a Form 6-K on October 14, 2025, for the month of October 2025. The company, previously known as Evaxion Biotech A/S until October 14, 2020, is a foreign private issuer based in Hoersholm, Denmark. It operates in the biological products sector and is required to file annual reports under Form 20-F.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Evaxion A/S's ongoing compliance and reporting as a foreign private issuer.

Risk Assessment

Risk Level: low — This filing is a routine operational report and does not contain significant new financial or strategic information that would inherently increase risk.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

This Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2025.

When was Evaxion A/S previously known by another name?

Evaxion A/S was formerly known as Evaxion Biotech A/S, with a date of name change on October 14, 2020.

Where is Evaxion A/S's principal executive office located?

Evaxion A/S's principal executive office is located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Does Evaxion A/S file annual reports under Form 20-F or Form 40-F?

Evaxion A/S indicates it files annual reports under cover of Form 20-F.

What is Evaxion A/S's Standard Industrial Classification code?

Evaxion A/S's Standard Industrial Classification code is 2836, for Biological Products (no diagnostic substances).

From the Filing

0001171843-25-006411.txt : 20251014 0001171843-25-006411.hdr.sgml : 20251014 20251014061523 ACCESSION NUMBER: 0001171843-25-006411 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20251013 FILED AS OF DATE: 20251014 DATE AS OF CHANGE: 20251014 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 251389369 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_101325.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On October 13, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits  Exhibit No.   Description       99.1   Evaxion to present a breadth of data from phase 2

View on Read The Filing